SNGX (BioPharma Bio) Earnings per share growth rate in current year

Official company branding of soligenix.com (SNGX)

Soligenix, Inc. (SNGX) balances its portfolio between civil defense and the treatment of rare pathologies. The annual change in earnings per share reflects the dynamics of this strategy, where 80.50 determines the current status of the parameter. Growth is driven by government contracts and low-cost molecular synthesis, although R&D success regarding lymphoma requires strict cost control to maintain financial stability.

soligenix.com (SNGX): Net earnings per share growth this year from 07/04/2022 to 11/13/2026

Analytical breakdowns and data insights for company soligenix.com (SNGX)

- current price and projected stock value:
Quote Chart Soligenix|SNGX - Analyst Consensus Forecast
- business market valuation indicators:
Market Value SNGX|SNGX - Enterprise Value
- balance sheet equity data:
Accounting Value per Share Soligenix|SNGX - Company Net Assets|Market Cap to Book Value Multiple soligenix.com|SNGX - Company Total Assets
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Soligenix, Inc.|SNGX - Long-Term Debt to Equity|Current Liabilities to Capital Soligenix|SNGX - Company Debts|Debt to Book Value Ratio SNGX|SNGX - Company Long-Term Debt|Short-Term Debt Volume Soligenix|Interim Coverage Ratio soligenix.com
- net income and valuation ratios data:
SNGX - Company Net Income|Expected Net Profit Soligenix, Inc.|SNGX - Price to Earnings Ratio|Future Price to Earnings Soligenix|SNGX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio SNGX|SNGX - Operating profit EBITDA|Net earnings per share for the trailing year Soligenix|SNGX - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months soligenix.com|SNGX - Earnings per share growth in current year|Projected earnings per share growth rate for next year Soligenix, Inc.
- company sales and revenue statistics:
SNGX - Revenue and Sales Volume
Basic company analysis:BioPharma Bio
Mass-produced product of Soligenix, Inc.

This indicator measures the annual dynamics of earnings per share, reflecting the efficiency of shareholder value generation. A positive trajectory confirms growth in profitability, while sharp peaks signal potential market overheating. By analyzing the annual growth vector of earnings per share, one can assess the impact of low operating expenses at Soligenix, Inc. (SNGX) amid the outsourcing of tests. A compact staff of specialists minimizes costs, stabilizing fundamental metrics. This provides capital protection against sharp volatile drawdowns.

Main competitors

Earnings per share trend in current year SMMT (Summit Therapeutics plc)|MRNA (Moderna Corp) - Earnings growth in current year|Earnings per share growth rate in current year SutroVax PCVX|Earnings growth in current year TARS|Net earnings per share growth this year cormedix.com CRMD|Seres Therapeutics, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year SPRO (Spero Therapeutics Inc)|Scynexis - Earnings growth in current year|Expected net earnings per share growth this year AN2 Therapeutics, Inc. ANTX|polypid.com (PYPD) - Earnings per share growth in current year|Earnings per share growth rate in current year ysbiopharm.com (LSB)|Earnings per share growth in current year Iterum Therapeutics PLC|Earnings per share growth this year PHGE (BiomX Ltd)|Earnings per share growth in current year 60 Degrees Pharmaceuticals (SXTP)|Expected net earnings per share growth this year oragenics.com|Earnings per share growth in current year OpGen, Inc. OPGN